Perrigo Company plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Perrigo Company plc on November 24, 2014. The filing details the execution of a Share Purchase Agreement dated November 6, 2014, for the acquisition of Omega Pharma Invest NV ("Omega"). The transaction is expected to close during the third quarter of Perrigo's fiscal 2015, subject to closing conditions.
Key Financial Metrics and Transaction Terms
- Acquisition Target: 685,348,257 shares of Omega, representing 95.77% of issued and outstanding share capital.
- Cash Consideration: EUR 1,845,983,131 to be paid to sellers.
- Non-Cash Consideration: 5,397,711 shares of Perrigo Company plc to be issued to Alychlo NV.
- Debt Assumption: Perrigo intends to assume or repay/redeem all outstanding indebtedness of Omega and its subsidiaries.
- Interest Adjustment: The Acquisition Consideration will increase by interest on EUR 2.48 billion from September 30, 2014, until completion, starting at a rate of 5% with monthly increases.
- Financing Sources: Borrowings under credit facilities, an equity offering (announced November 20, 2014), and an issuance of senior notes by Perrigo Finance plc.
Material Changes and Pro Forma Data
The filing incorporates unaudited pro forma condensed combined financial statements as Exhibit 99.1. These statements reflect the acquisition of Omega, the equity offering, and the notes offering as if they occurred on September 27, 2014 (balance sheet) and June 30, 2013 (statements of operations). The filing does not provide specific numerical values for revenue, profit, or margins within the text of this report; investors must refer to the attached Exhibit 99.1 for detailed pro forma figures.
Outlook, Risks, and Contingencies
The completion of the acquisition is contingent upon the satisfaction or waiver of certain closing conditions. The transaction involves significant leverage through new debt issuances and credit facility borrowings. The filing references a prior acquisition of Elan Corporation, plc, completed on December 18, 2013, which is also factored into the pro forma fiscal year ended June 28, 2014.
Key Facts for Investor Verification
- Verify the specific pro forma financial metrics (revenue, EBITDA, debt levels) in Exhibit 99.1, as they are not detailed in the narrative text.
- Confirm the status of closing conditions required to finalize the Omega acquisition in Q3 fiscal 2015.
- Review the terms of the new senior notes and equity offering to assess the impact on capital structure and dilution.
- Monitor the interest rate adjustments on the EUR 2.48 billion base amount, which will increase the total acquisition cost.